EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Modified-Release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-Blind, Randomized, Placebo-Controlled Trials

Axel Dignass, Wolfgang Stremmel, Marek Horyński, Oleksandr Poyda, Peter Armerding, Klaus Fellermann, Jost Langhorst, Tanja Kuehbacher, Peter Uebel, Juergen Stein, Gottfried Novacek, Elena Avalueva und 8 weitere

Clinical Gastroenterology and Hepatology · 2024

DOI: 10.1016/j.cgh.2023.09.031 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024. Verfasst von Axel Dignass und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine I, Agaplesion Markus Krankenhaus, Frankfurt am Main, Germany. Electronic address: axel.dignass@agaplesion.de. Hauptthemen laut MEDLINE: Colitis, Ulcerative. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Dr. Falk Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: The aim of this study was to evaluate the efficacy of LT-02, a novel modified-release phosphatidylcholine (PC) formulation, for induction and maintenance of remission in patients with mild to moderate ulcerative colitis (UC) and inadequate response to mesalamine. METHODS: LT-02 was evaluated in a multicenter double-blind, randomized, placebo-controlled study comprising a 12-week induction trial (PCG-2), followed by a 48-week maintenance trial (PCG-4). In PCG-2, patients were randomized 1:1:1 to treatment with 0.8 g LT-02 4 times daily (QID), 1.6 g LT-02 twice daily (BID), or placebo, respectively. All patients continued to take a standard dose of oral mesalamine (≥2.4 g/day). The primary end point in PCG-2 was deep remission. Patients achieving remission at week 12 were randomly assigned 2:1:1 to 1.6 g LT-02 BID, placebo, or 500 mg mesalamine (3 times daily), respectively, in PCG-4; the primary end point was remission at 48 weeks. RESULTS: PCG-2 was terminated early for futility after a prespecified interim analysis; 466 patients (of 762 planned) were randomized. There was no statistically significant difference in deep remission at week 12 (placebo, 13.5%; LT-02 BID, 14.2%; LT-02 QID, 9.7%). In PCG-4, 150 patients (of approximately 400 planned) were randomized. There was no statistically significant difference in remission rates at week 48 (LT-02 BID, 49.3%; mesalamine, 50.0%; placebo, 43.2%). LT-02 was safe. CONCLUSIONS: Despite prior evidence of beneficial effects of PC in phase 2 trials, our induction study with LT-02 in patients with mild to moderate UC was terminated prematurely for futility. Signals of efficacy in maintenance therapy require confirmation in an adequately powered maintenance trial. LT-02 was safe and well-tolerated. CLINICALTRIALS: gov: NCT02280629, NCT02142725.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeHumansMesalamineAnti-Inflammatory Agents, Non-SteroidalPhosphatidylcholinesRemission InductionDouble-Blind MethodTreatment Outcome

Stichwörter der Autor:innen

MesalamineMucusPhosphatidylcholineUlcerative Colitis

Substanzen

MesalamineAnti-Inflammatory Agents, Non-SteroidalPhosphatidylcholines

Autor:innen und Institutionen

  • Department of Medicine I, Agaplesion Markus Krankenhaus, Frankfurt am Main, Germany. Electronic address: axel.dignass@agaplesion.de.
  • Department of Gastroenterology, University Hospital of Heidelberg, Heidelberg, Germany.
  • Endoskopia Sp., Sopot, Poland.
  • Department of Proctology, O.O. Bogomolets National Medical University, Kyiv, Ukraine.
  • Praxis für Gastroenterologie, Berlin, Germany.
  • Division of Gastroenterology, Medical Department I, Campus Lübeck, University Hospital of Schleswig-Holstein, Lübeck, Germany.

Förderung

  • Dr. Falk Pharma

Zitieren

APA

Dignass, A., Stremmel, W., Horyński, M., Poyda, O., Armerding, P., Fellermann, K., Langhorst, J., Kuehbacher, T., Uebel, P., Stein, J., Novacek, G., Avalueva, E., Oliinyk, O., Hasselblatt, P., Dorofeyev, A., Heinemann, H., Mueller, R., Greinwald, R., Reinisch, W., & International PROTECT-1/2 Study Groups (2024). Modified-Release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-Blind, Randomized, Placebo-Controlled Trials. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2023.09.031

Vancouver

Dignass A, Stremmel W, Horyński M, Poyda O, Armerding P, Fellermann K, et al. Modified-Release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-Blind, Randomized, Placebo-Controlled Trials. Clinical Gastroenterology and Hepatology. 2024. doi:10.1016/j.cgh.2023.09.031

BibTeX
@article{Dignass2024,
  author = {Dignass, Axel and Stremmel, Wolfgang and Horyński, Marek and Poyda, Oleksandr and Armerding, Peter and Fellermann, Klaus and Langhorst, Jost and Kuehbacher, Tanja and Uebel, Peter and Stein, Juergen and Novacek, Gottfried and Avalueva, Elena and Oliinyk, Oleksandr and Hasselblatt, Peter and Dorofeyev, Andrey and Heinemann, Heidrun and Mueller, Ralph and Greinwald, Roland and Reinisch, Walter and International PROTECT-1/2 Study Groups, International PROTECT-1/2 Study Groups},
  title = {Modified-Release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-Blind, Randomized, Placebo-Controlled Trials},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2024},
  doi = {10.1016/j.cgh.2023.09.031}
}
Kostenlos starten →